Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of Translational Medicine, Bristol Myers Squibb, discuss the challenges, progress, and potential of CAR T-cell therapy. Cell therapy research is now advancing beyond cancer to target cells contributing to other chronic diseases.
Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.Michaela Liedtke, MD, of @StanfordMed, discusses #CARTcell #immunotherapy for #multiplemyeloma.
Larry Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, Texas, discusses findings from the 5-year follow-up analysis of the KarMMa trial of idecabtagene vicleucel in patients…
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tara K. Gregory, MD, Colorado Blood Cancer Institute, Denver, Colorado, discusses CAR T-cell therapy for multiple myeloma. Dr Gregory reviews steps involved in CAR T-cell therapy, potential outcomes…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from a recent study of real-world…
Michael Wang, MD, professor, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from the TRANSCEND-NHL-001 study, which was designed to investigate…
